2026 H1 -tulosraportti
8 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??
From Chatgpt: August 5: First commercial delivery from AlphaOne Thor Medical announced that the first customer delivery of high-purity Thorium-228 (Th-228) from AlphaOne at Herøya had been completed. This marked the start of commercial delivery from the factory. August 28: More customers confirmed In the half-year report, Thor Medical stated that the company had completed deliveries to: * Minerva Imaging * Node Pharma * other Pb-212 customers
·6 t sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?First, the value of Thor Medical fell 16 percent after the presentation of the first half-year results on August 28 – from 6.79 to 5.68 kroner per share. The company then delivered lower sales revenues than most had hoped for, guided further revenues in "the low double-digit million range" for the full year 2026 and simultaneously presented a cash balance of 60 million kroner after having burned through 120 million in cash in the first half-year. For those following the stock, a share issue notice immediately hung in the air, which strongly contributed to the share price drop on the results day. On Friday, September 4, the stock then fell almost 11 percent from Thursday's closing price. This followed an actual completed share issue of 300 million kroner on Thursday evening, and where the stock on Friday went ex-right to participate in a repair issue of an additional 45 million kroner. The share price started Friday in the area of 4.9 kroner, while mathematically it should not have fallen to more than 5.35 kroner given how the share issue was priced compared to Thursday's closing price and the size of the share issue. Is the market therefore overreacting to the share issue? A share issue that the company presents as offensive. Thor Medical says most of the money will be used to build a downstream production and distribution line in the USA. It is a natural next step after the upstream factory at Herøya is now up and running. Thor Medical must establish itself in the USA if their radioactive isotopes are to be used by pharmaceutical companies "over there". The company's absolute main product has a half-life of less than half a day. But the share issue provides a brutal reminder of the risk of investing in a company like Thor Medical. The company is dependent on other pharmaceutical companies developing and getting approved medicines that Thor Medical's radioactive isotopes can then be linked with. In an analysis dated September 3 from the brokerage firm DNB Carnegie, it states that the analyst expects no such approved therapies before 2030 at the earliest. Thus, Thor Medical will long remain dependent on much more limited revenues from sales to pharmaceutical companies' clinical studies, and perhaps will therefore also have to top up with more share issues. Such issues should ideally be announced in the future right after good news and not, as now, right after the half-year results indicated that the cash reserves were about to run dry. DNB Carnegie recommended selling and a price target of 4.2 kroner in an analysis early Thursday morning, while the share issue was first announced after the stock exchange closed on Thursday evening. It should nevertheless be added that the brokerage firm then sharply adjusted its price target from a previous mere 3.5 kroner (!). Mathematically (again), the share issue should not significantly affect the brokerage firm's price target. Thor Medical has no other major industrial investors than the main shareholder Scatec Innovation, John Andersen's company, who is Alf Bjørnseth's son-in-law. The shareholders are otherwise private investors or purely financial. Two or three of them had additionally either sold out completely or significantly reduced their holdings earlier in August. This did not give the brokerage firms ABG Sundal Collier and Arctic Securities, who raised the money for Thor Medical on Thursday evening, the best negotiating cards against potential investors. Scatec Innovation's lending of shares to the participating investors gave those among them who wanted to exit quickly the opportunity to sell immediately and gain an almost risk-free profit of 2–4 percent (most shares were traded on Friday in the range of 4.9-5.0 kroner) for one evening hour's work on Thursday.
·8 t sittenDnB Carnegie has biotech/pharma projects underway .. NB ! breathes life into some Norwegian companies to control the sheep flocks and their investor kr.
·10 t sittenHave they previously said anything about the expected cost of building up alpha two? Is it just me who thinks that 300 mill sounds a bit low?Thor medical customers in USA : RadioMedix 5-year framework agreement Global pharma company Telix Pharmaceuticals
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
8 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??From Chatgpt: August 5: First commercial delivery from AlphaOne Thor Medical announced that the first customer delivery of high-purity Thorium-228 (Th-228) from AlphaOne at Herøya had been completed. This marked the start of commercial delivery from the factory. August 28: More customers confirmed In the half-year report, Thor Medical stated that the company had completed deliveries to: * Minerva Imaging * Node Pharma * other Pb-212 customers
- ·6 t sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?First, the value of Thor Medical fell 16 percent after the presentation of the first half-year results on August 28 – from 6.79 to 5.68 kroner per share. The company then delivered lower sales revenues than most had hoped for, guided further revenues in "the low double-digit million range" for the full year 2026 and simultaneously presented a cash balance of 60 million kroner after having burned through 120 million in cash in the first half-year. For those following the stock, a share issue notice immediately hung in the air, which strongly contributed to the share price drop on the results day. On Friday, September 4, the stock then fell almost 11 percent from Thursday's closing price. This followed an actual completed share issue of 300 million kroner on Thursday evening, and where the stock on Friday went ex-right to participate in a repair issue of an additional 45 million kroner. The share price started Friday in the area of 4.9 kroner, while mathematically it should not have fallen to more than 5.35 kroner given how the share issue was priced compared to Thursday's closing price and the size of the share issue. Is the market therefore overreacting to the share issue? A share issue that the company presents as offensive. Thor Medical says most of the money will be used to build a downstream production and distribution line in the USA. It is a natural next step after the upstream factory at Herøya is now up and running. Thor Medical must establish itself in the USA if their radioactive isotopes are to be used by pharmaceutical companies "over there". The company's absolute main product has a half-life of less than half a day. But the share issue provides a brutal reminder of the risk of investing in a company like Thor Medical. The company is dependent on other pharmaceutical companies developing and getting approved medicines that Thor Medical's radioactive isotopes can then be linked with. In an analysis dated September 3 from the brokerage firm DNB Carnegie, it states that the analyst expects no such approved therapies before 2030 at the earliest. Thus, Thor Medical will long remain dependent on much more limited revenues from sales to pharmaceutical companies' clinical studies, and perhaps will therefore also have to top up with more share issues. Such issues should ideally be announced in the future right after good news and not, as now, right after the half-year results indicated that the cash reserves were about to run dry. DNB Carnegie recommended selling and a price target of 4.2 kroner in an analysis early Thursday morning, while the share issue was first announced after the stock exchange closed on Thursday evening. It should nevertheless be added that the brokerage firm then sharply adjusted its price target from a previous mere 3.5 kroner (!). Mathematically (again), the share issue should not significantly affect the brokerage firm's price target. Thor Medical has no other major industrial investors than the main shareholder Scatec Innovation, John Andersen's company, who is Alf Bjørnseth's son-in-law. The shareholders are otherwise private investors or purely financial. Two or three of them had additionally either sold out completely or significantly reduced their holdings earlier in August. This did not give the brokerage firms ABG Sundal Collier and Arctic Securities, who raised the money for Thor Medical on Thursday evening, the best negotiating cards against potential investors. Scatec Innovation's lending of shares to the participating investors gave those among them who wanted to exit quickly the opportunity to sell immediately and gain an almost risk-free profit of 2–4 percent (most shares were traded on Friday in the range of 4.9-5.0 kroner) for one evening hour's work on Thursday.
- ·8 t sittenDnB Carnegie has biotech/pharma projects underway .. NB ! breathes life into some Norwegian companies to control the sheep flocks and their investor kr.
- ·10 t sittenHave they previously said anything about the expected cost of building up alpha two? Is it just me who thinks that 300 mill sounds a bit low?Thor medical customers in USA : RadioMedix 5-year framework agreement Global pharma company Telix Pharmaceuticals
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
8 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??From Chatgpt: August 5: First commercial delivery from AlphaOne Thor Medical announced that the first customer delivery of high-purity Thorium-228 (Th-228) from AlphaOne at Herøya had been completed. This marked the start of commercial delivery from the factory. August 28: More customers confirmed In the half-year report, Thor Medical stated that the company had completed deliveries to: * Minerva Imaging * Node Pharma * other Pb-212 customers
- ·6 t sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?First, the value of Thor Medical fell 16 percent after the presentation of the first half-year results on August 28 – from 6.79 to 5.68 kroner per share. The company then delivered lower sales revenues than most had hoped for, guided further revenues in "the low double-digit million range" for the full year 2026 and simultaneously presented a cash balance of 60 million kroner after having burned through 120 million in cash in the first half-year. For those following the stock, a share issue notice immediately hung in the air, which strongly contributed to the share price drop on the results day. On Friday, September 4, the stock then fell almost 11 percent from Thursday's closing price. This followed an actual completed share issue of 300 million kroner on Thursday evening, and where the stock on Friday went ex-right to participate in a repair issue of an additional 45 million kroner. The share price started Friday in the area of 4.9 kroner, while mathematically it should not have fallen to more than 5.35 kroner given how the share issue was priced compared to Thursday's closing price and the size of the share issue. Is the market therefore overreacting to the share issue? A share issue that the company presents as offensive. Thor Medical says most of the money will be used to build a downstream production and distribution line in the USA. It is a natural next step after the upstream factory at Herøya is now up and running. Thor Medical must establish itself in the USA if their radioactive isotopes are to be used by pharmaceutical companies "over there". The company's absolute main product has a half-life of less than half a day. But the share issue provides a brutal reminder of the risk of investing in a company like Thor Medical. The company is dependent on other pharmaceutical companies developing and getting approved medicines that Thor Medical's radioactive isotopes can then be linked with. In an analysis dated September 3 from the brokerage firm DNB Carnegie, it states that the analyst expects no such approved therapies before 2030 at the earliest. Thus, Thor Medical will long remain dependent on much more limited revenues from sales to pharmaceutical companies' clinical studies, and perhaps will therefore also have to top up with more share issues. Such issues should ideally be announced in the future right after good news and not, as now, right after the half-year results indicated that the cash reserves were about to run dry. DNB Carnegie recommended selling and a price target of 4.2 kroner in an analysis early Thursday morning, while the share issue was first announced after the stock exchange closed on Thursday evening. It should nevertheless be added that the brokerage firm then sharply adjusted its price target from a previous mere 3.5 kroner (!). Mathematically (again), the share issue should not significantly affect the brokerage firm's price target. Thor Medical has no other major industrial investors than the main shareholder Scatec Innovation, John Andersen's company, who is Alf Bjørnseth's son-in-law. The shareholders are otherwise private investors or purely financial. Two or three of them had additionally either sold out completely or significantly reduced their holdings earlier in August. This did not give the brokerage firms ABG Sundal Collier and Arctic Securities, who raised the money for Thor Medical on Thursday evening, the best negotiating cards against potential investors. Scatec Innovation's lending of shares to the participating investors gave those among them who wanted to exit quickly the opportunity to sell immediately and gain an almost risk-free profit of 2–4 percent (most shares were traded on Friday in the range of 4.9-5.0 kroner) for one evening hour's work on Thursday.
- ·8 t sittenDnB Carnegie has biotech/pharma projects underway .. NB ! breathes life into some Norwegian companies to control the sheep flocks and their investor kr.
- ·10 t sittenHave they previously said anything about the expected cost of building up alpha two? Is it just me who thinks that 300 mill sounds a bit low?Thor medical customers in USA : RadioMedix 5-year framework agreement Global pharma company Telix Pharmaceuticals
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt